These Are the Sectors Best Liked Within Defensive and Cyclicals Groups – Morgan Stanley
Express News | Gilead : Mizuho Raises Target Price to $117 From $100
Notable Healthcare Headlines for the Week: Gilead, CVS Health, Sanofi in Focus
Gilead and Vertex Pharma Named Among Biotech's Tariff Safe Havens
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $117
Gilead Sciences (GILD) Gets a Buy From Mizuho Securities
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110
30 U.S. Picks Based on Up Vs. Down EPS Revisions and Dividend Payouts
10 Stocks Defying Wall Street Turbulence to Kick off the Month of May
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest
Gilead Sciences: Hold Rating Maintained Amid Near-Term Challenges and Limited Growth Prospects
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences Agrees to Pay $202 Million to Settle Claims of Kickbacks to Doctors for HIV Drug Prescriptions
Express News | U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors
CIBC Introducing Additional U.S. Canadian Depositary Receipts
Gilead To Present New Research To EASL Congress
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV's Impact in the United States
Investors in Gilead Sciences (NASDAQ:GILD) Have Seen Favorable Returns of 98% Over the Past Three Years
BofA Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $126
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating